| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Sensyne Health plc (LSE: SENS)
SENS Technical Analysis
5
| As on 17th Jun 2022 SENS STOCK Price closed @ 0.35 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 141.38 & Strong Sell for SHORT-TERM with Stoploss of 157.15 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SENSSTOCK Price
| Open | 0.52 | Change | Price | % |
| High | 0.60 | 1 Day | -0.29 | -45.31 |
| Low | 0.16 | 1 Week | -0.55 | -61.11 |
| Close | 0.35 | 1 Month | -1.55 | -81.58 |
| Volume | 4449143 | 1 Year | -112.15 | -99.69 |
| 52 Week High 185.00 | 52 Week Low 0.02 | ||||
LSE UK Most Active Stocks
| DKE | 0.15 | 0.00% |
| NNN | 0.09 | 50.00% |
| SYME | 0.10 | -9.09% |
| DMTR | 0.03 | 0.00% |
| PREM | 0.53 | 3.92% |
| MCLS | 1.68 | 46.09% |
| YGEN | 0.49 | 0.00% |
| CLON | 0.11 | 0.00% |
| VOD | 71.04 | 0.57% |
| BOIL | 0.10 | 0.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
| SENS Daily Charts |
SENS Intraday Charts |
Whats New @ Bazaartrend |
SENS Free Analysis |
|
|
SENS Important Levels Intraday
| RESISTANCE | 1.20 |
| RESISTANCE | 0.93 |
| RESISTANCE | 0.76 |
| RESISTANCE | 0.59 |
| SUPPORT | 0.11 |
| SUPPORT | -0.06 |
| SUPPORT | -0.23 |
| SUPPORT | -0.50 |
SENS Forecast May 2024
| 4th UP Forecast | 102.48 |
| 3rd UP Forecast | 69.73 |
| 2nd UP Forecast | 49.48 |
| 1st UP Forecast | 29.24 |
| 1st DOWN Forecast | -28.54 |
| 2nd DOWN Forecast | -48.78 |
| 3rd DOWN Forecast | -69.03 |
| 4th DOWN Forecast | -101.78 |
SENS Weekly Forecast
| 4th UP Forecast | 58.16 |
| 3rd UP Forecast | 39.62 |
| 2nd UP Forecast | 28.16 |
| 1st UP Forecast | 16.70 |
| 1st DOWN Forecast | -16.00 |
| 2nd DOWN Forecast | -27.46 |
| 3rd DOWN Forecast | -38.92 |
| 4th DOWN Forecast | -57.46 |
SENS Forecast2024
| 4th UP Forecast | 366.44 |
| 3rd UP Forecast | 249.03 |
| 2nd UP Forecast | 176.46 |
| 1st UP Forecast | 103.89 |
| 1st DOWN Forecast | -103.19 |
| 2nd DOWN Forecast | -175.76 |
| 3rd DOWN Forecast | -248.33 |
| 4th DOWN Forecast | -365.74 |
Sensyne Health plc ( LSE UK Symbol : SENS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SENS Business Profile
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for coronavirus self-monitoring; DBm-Health, which helps individuals monitor their blood glucose levels and share their readings with health care professionals; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include SEND, an early warning system for monitoring patient vital signs in hospital; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; and Support-HF, a prescribed digital therapeutic for monitoring heart failure at home. Sensyne Health has strategic research alliance with Bayer to develop new treatments using clinical artificial intelligence; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Milton Keynes University Hospital NHS Foundation Trust to enable the ethical application of clinical artificial intelligence research to improve patient care and research into new medicines; collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; and strategic research agreement with Hampshire Hospitals NHS Foundation Trust. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom. Address: Schrodinger Building, Oxford, United Kingdom, OX4 4GE
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service